Back to News
Market Impact: 0.3
Sionna Advances New CF Combo To Phase 2a After SION-719 Setback, Cuts Workforce 46%; Stock Down
Source: Nasdaq
Healthcare & BiotechProduct Launches
Sionna Therapeutics plans to advance its SION-451 plus SION-2222 dual combination into the AscenSION CF Phase 2a proof-of-concept trial for cystic fibrosis. The clinical progression is a positive development for the company’s pipeline, though efficacy and safety data have not yet been reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SION0.55
More News
- Backbone of a beast – charting Nvidia's rise to networking titan
- Anthropic's IPO push includes a big bet on life sciences
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat